Gupta Haripriya, Min Byeong-Hyun, Ganesan Raja, Gebru Yoseph Asmelash, Sharma Satya Priya, Park Eunju, Won Sung-Min, Jeong Jin-Ju, Lee Su-Been, Cha Min-Gi, Kwon Goo-Hyun, Jeong Min-Kyo, Hyun Ji-Ye, Eom Jung-A, Park Hee-Jin, Yoon Sang-Jun, Choi Mi-Ran, Kim Dong-Joon, Suk Ki-Tae
Institute for Liver and Digestive Diseases, College of Medicine, Hallym University, Chuncheon 24252, Korea.
Biomedicines. 2022 Feb 25;10(3):550. doi: 10.3390/biomedicines10030550.
Non-alcoholic fatty liver disease (NAFLD) is considered to be a significant health threat globally, and has attracted growing concern in the research field of liver diseases. NAFLD comprises multifarious fatty degenerative disorders in the liver, including simple steatosis, steatohepatitis and fibrosis. The fundamental pathophysiology of NAFLD is complex and multifactor-driven. In addition to viruses, metabolic syndrome and alcohol, evidence has recently indicated that the microbiome is related to the development and progression of NAFLD. In this review, we summarize the possible microbiota-based therapeutic approaches and highlight the importance of establishing the diagnosis of NAFLD through the different spectra of the disease via the gut-liver axis.
非酒精性脂肪性肝病（NAFLD）被认为是全球范围内对健康的重大威胁，并且在肝脏疾病研究领域引起了越来越多的关注。NAFLD包括肝脏中多种脂肪变性疾病，包括单纯性脂肪变性、脂肪性肝炎和纤维化。NAFLD的基本病理生理学是复杂的且由多因素驱动。除了病毒、代谢综合征和酒精外，最近有证据表明微生物群与NAFLD的发生和发展有关。在本综述中，我们总结了基于微生物群的可能治疗方法，并强调了通过肠-肝轴根据疾病的不同谱型建立NAFLD诊断的重要性。
